Oral Pharmaceutical Formulations for bone resorption inhibitor
Publication Date: 2003-Mar-14
The IP.com Prior Art Database
Oral Pharmaceutical Formulations for Bone Resorption Inhibitor
Sustained, controlled or immediate release oral dosage forms capable of releasing the active pharmaceutical ingredient represented by the chemical formula shown in Figure 1, optionally in the form of its monosodium salt trihydrate, to human patients immediately or over extended periods following administration may contain the following active and inactive ingredients: 15% to 25% of the active pharmaceutical ingredient represented by the chemical formula shown in Figure 1, optionally in the form of its monosodium salt trihydrate, 20% to 30% of a naturally occurring clathrate e.g. betadex, 30% to 50% of a calcium hydrogen phosphate, 5%-15% of a sodium starch glycolate and optionally other conventional tabletting excipients selected from cross-linked cyclic amide polymers, known lubricants, opacifiers, glidants and/or anti-caking agents in amounts from 0.1% to 2%. All ranges are approximate and are expressed as percentage of the total dosage form by weight.
Said dosage forms may be administered or further processed in granulate, tablet or powder form as solid solutions, solid dispersions or mixtures thereof. Any known and as-yet undisclosed formulation methods may be used as-is or adapted in any manner to arrive at the formulations disclosed herein.